These findings reveal the potential therapeutic benefits of clinical application of MC‐4 with a lower dose of mTOR inhibitors for metastatic RCC patients by modulating cancer cell metabolism and autophagy. The gene discussed is MTOR; the disease is renal cell carcinoma.